Merck KGaA’s (MRK) Buy Rating Reaffirmed at UBS Group

UBS Group reissued their buy rating on shares of Merck KGaA (FRA:MRK) in a research note published on Monday morning.

Other analysts also recently issued reports about the company. Kepler Capital Markets set a €119.00 ($141.67) target price on Merck KGaA and gave the company a buy rating in a research note on Thursday, September 21st. Berenberg Bank set a €116.00 ($138.10) target price on Merck KGaA and gave the company a buy rating in a research note on Tuesday, September 19th. Warburg Research set a €115.00 ($136.90) target price on Merck KGaA and gave the company a buy rating in a research note on Tuesday, September 26th. Citigroup set a €123.00 ($146.43) target price on Merck KGaA and gave the company a buy rating in a research note on Monday, September 25th. Finally, Oddo Bhf set a €125.00 ($148.81) price target on Merck KGaA and gave the stock a buy rating in a research note on Friday, September 29th. Twelve investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Merck KGaA has an average rating of Hold and an average target price of €107.57 ($128.06).

Merck KGaA (FRA:MRK) traded up €1.58 ($1.88) during trading hours on Monday, hitting €92.84 ($110.52). 490,843 shares of the stock were exchanged. Merck KGaA has a twelve month low of €87.33 ($103.96) and a twelve month high of €115.00 ($136.90). The firm has a market capitalization of $11,900.00 and a price-to-earnings ratio of 21.74.

COPYRIGHT VIOLATION WARNING: This piece was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/16/merck-kgaas-mrk-buy-rating-reaffirmed-at-ubs-group.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply